Surgical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan.
Breast Cancer. 2011 Jan;18(1):10-7. doi: 10.1007/s12282-009-0186-9. Epub 2010 Jan 14.
To evaluate the safety and efficacy of radiofrequency ablation (RFA) as a local therapy for early breast carcinomas, we performed a phase I/II study at our institution.
Fifty patients with core-needle biopsy-proven breast carcinoma that was ≤ 3 cm in diameter on ultrasonography were enrolled in this study. Under ultrasound (US) guidance, the tumor and surrounding breast tissue were ablated with a saline-cooled RF electrode followed by immediate surgical resection. Resected specimens were examined by hematoxylin and eosin (H&E) staining and nicotinamide adenine dinucleotide (NADH) diaphorase staining to assess tumor viability.
Forty-nine patients completed the treatment. The mean tumor size was 1.70 cm. The mean ablation time was 8.7 min using a mean power of 48.5 W. Of the 49 treated patients, complete ablation was recognized in 30 patients (61%) by H&E staining and/or NADH diaphorase staining. The NADH viability staining was available for 38 patients, and in 29 (76.3%), there was no evidence of viable malignant cells. Of the 29 treated patients with breast carcinomas ≤ 2 cm in diameter examined by pathological examination, complete ablation was achieved in 24 patients (83%). Of the 26 treated patients with breast carcinomas without an extended intraductal component (EIC) according to pathological examination, complete ablation was determined in 22 patients (85%). RFA-related adverse events were observed in five cases: two with skin burn and three with muscle burns.
RF ablation is a safe and promising minimally invasive treatment for small breast carcinomas with pathological tumor size ≤ 2 cm in diameter and without EIC.
为了评估射频消融（RFA）作为早期乳腺癌局部治疗的安全性和有效性，我们在本机构进行了一项 I/II 期研究。
本研究纳入了 50 名经核心针活检证实的超声直径≤3cm 的乳腺癌患者。在超声（US）引导下，使用盐水冷却的 RF 电极对肿瘤及其周围乳腺组织进行消融，随后立即进行手术切除。切除标本用苏木精和伊红（H&E）染色和烟酰胺腺嘌呤二核苷酸（NADH）黄递酶染色进行检查，以评估肿瘤活力。
49 名患者完成了治疗。平均肿瘤大小为 1.70cm。使用平均功率 48.5W 的情况下，平均消融时间为 8.7 分钟。在 49 名接受治疗的患者中，通过 H&E 染色和/或 NADH 黄递酶染色，30 名患者（61%）确认完全消融。NADH 活力染色可用于 38 名患者，其中 29 名（76.3%）没有恶性细胞存活的证据。在 29 名接受直径≤2cm 的乳腺癌病理检查的患者中，24 名（83%）实现了完全消融。在 26 名接受病理检查无扩展管内成分（EIC）的乳腺癌患者中，22 名（85%）确定了完全消融。在 5 例患者中观察到与 RFA 相关的不良事件：2 例皮肤烧伤，3 例肌肉烧伤。
对于直径≤2cm 且无 EIC 的病理肿瘤大小的小乳腺癌，RFA 是一种安全且有前途的微创治疗方法。
